Somewhat Positive Media Coverage Extremely Likely to Affect Tetraphase Pharmaceuticals (TTPH) Share Price

Press coverage about Tetraphase Pharmaceuticals (NASDAQ:TTPH) has trended somewhat positive on Saturday, AlphaOne Sentiment Analysis reports. AlphaOne, a unit of Accern, ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Tetraphase Pharmaceuticals earned a daily sentiment score of 0.24 on AlphaOne’s scale. AlphaOne also gave media stories about the biopharmaceutical company an impact score of 93 out of 100, meaning that recent press coverage is extremely likely to have an impact on the stock’s share price in the near term.

These are some of the news articles that may have impacted Alpha One Sentiment Analysis’s scoring:

Insider Buying and Selling by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

A number of analysts recently commented on TTPH shares. BMO Capital Markets reaffirmed a “buy” rating and issued a $12.00 target price on shares of Tetraphase Pharmaceuticals in a research report on Monday, May 15th. Stifel Nicolaus boosted their target price on Tetraphase Pharmaceuticals from $5.00 to $7.00 and gave the company a “hold” rating in a research report on Thursday, March 9th. Finally, Zacks Investment Research lowered Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, May 10th.

Tetraphase Pharmaceuticals (NASDAQ TTPH) traded down 1.49% during trading on Friday, reaching $7.27. The company’s stock had a trading volume of 326,907 shares. The company has a 50-day moving average of $7.47 and a 200 day moving average of $6.21. Tetraphase Pharmaceuticals has a one year low of $3.11 and a one year high of $9.93. The firm’s market cap is $275.94 million.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported ($0.79) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.60) by $0.19. Tetraphase Pharmaceuticals had a negative net margin of 1,932.24% and a negative return on equity of 60.55%. The business had revenue of $1.48 million for the quarter, compared to the consensus estimate of $1.46 million. During the same period in the prior year, the business posted ($0.46) EPS. Tetraphase Pharmaceuticals’s revenue for the quarter was down 24.5% on a year-over-year basis. Analysts expect that Tetraphase Pharmaceuticals will post ($2.80) EPS for the current fiscal year.

WARNING: “Somewhat Positive Media Coverage Extremely Likely to Affect Tetraphase Pharmaceuticals (TTPH) Share Price” was reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.

Leave a Reply